Goldman Sachs Maintains Buy on Gossamer Bio, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi has reiterated a Buy rating on Gossamer Bio (NASDAQ:GOSS) and maintained a price target of $8.
June 17, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Paul Choi has reiterated a Buy rating on Gossamer Bio and maintained a price target of $8.
The reiteration of a Buy rating and a maintained price target of $8 by a reputable analyst from Goldman Sachs is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100